Latest Regulation News

Matsa Resources has advised shareholders to take no immediate action following Patronus Resources’ unsolicited takeover offer, with a formal recommendation expected soon.

Gyder Surgical, backed by Hydrix Ventures, has secured FDA 510(k) clearance for its innovative GYDER Hip System, opening the door to the lucrative U.S. market and increasing Hydrix’s investment value.

CLINUVEL has released preliminary data from its CUV052 study showing SCENESSE® is well tolerated in adolescent erythropoietic protoporphyria (EPP) patients, supporting a planned label extension in 2025.

Cleo Diagnostics has responded to an ASX price query following a notable rise in its share price and trading volume, underscoring its patented ovarian cancer detection technology and ongoing U.S. clinical trials.

Lanthanein Resources has completed diamond drilling at its Lady Grey Project, targeting a significant EM conductor plate aligned with gold anomalies. Approval for further drilling under a higher-grade anomaly sets the stage for potential resource expansion.

AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.

Shekel Brainweigh Ltd has requested an immediate suspension from ASX quotation as it moves towards removal from the official ASX list, raising questions about the company’s future.

AdAlta has fast-tracked its cellular immunotherapy growth by signing two new term sheets for clinical-stage CAR-T products from Asia, pivoting to focus on in-licensing and clinical trials while winding down internal R&D on its antifibrotic drug AD-214.

Vitrafy Life Sciences reports strong progress in cryopreservation technology development and US market expansion following a successful $35 million IPO. The company highlights improved biological sample preservation outcomes and strategic commercial milestones.

Brookfield Capital Partners has submitted a non-binding proposal to acquire Insignia Financial at A$4.60 per share, matching rival offers and setting the stage for a competitive bidding process.

Neurizon Therapeutics has been granted a pivotal US patent for its lead drug candidate NUZ-001, extending protection until 2039 and enhancing its commercial and clinical positioning in neurodegenerative disease treatment.

SportsHero has secured a two-year deal with Indonesia’s third-largest telco, XL Axiata, to market its iGV Family Game Pass, leveraging Direct Carrier Billing to tap into 8.3 million PC gamers. This partnership positions SportsHero at the forefront of Southeast Asia’s rapidly growing esports sector.